The Employees’ State Insurance Corporation (ESIC) on February 14, 2026, issued Amendment 03/2026 under F. No. U-25/12/RC/RateRevision/2026/Med.V (E:1550528)/37 regarding downward rate revision for various items covered under DGESIC Rate Contracts (RCs) 165, 166, 167 and 169, originally notified vide reference dated December 12, 2025 (valid from 11.12.2025 to 10.12.2027).
The amendment revises rates downward for specified high-value drugs supplied by firms including M/s Novo Nordisk India Private Limited, M/s Bayer Pharmaceuticals Pvt. Ltd., M/s Roche Products (India) Private Limited and M/s Tablet (India) Limited. Revised rates (GST extra) are effective from 11.12.2025 and apply to items such as Human Coagulation Factor VII (NovoSeven), Aflibercept Injection (Eylea), Faricimab (Vabysmo), Pertuzumab + Trastuzumab (Phesgo), Polatuzumab (Polivy), and Multivitamin Infusion (Tilvit), as detailed in the annexed tables.
All DDOs have been directed to recover excess payments made for supply orders placed on or after 11.12.2025 by adjusting the differential amount from subsequent bills of the concerned firms and to maintain proper records. Reconciliation and recovery under this amendment shall be the sole responsibility of the Competent Authority/DDOs of the respective institutions.
[Notification No. U-25/12/RC/RateRevision/2026/Med.V (E:1550528)/37]
